Emavusertib

CAS No. 1801344-14-8

Emavusertib( CA-4948 )

Catalog No. M23815 CAS No. 1801344-14-8

Emavusertib is a potent IRAK4/FLT3 inhibtor. CA-4948 with anti-tumor activity.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
2MG 40 In Stock
5MG 63 In Stock
10MG 80 In Stock
25MG 160 In Stock
50MG 295 In Stock
100MG 507 In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    Emavusertib
  • Note
    Research use only, not for human use.
  • Brief Description
    Emavusertib is a potent IRAK4/FLT3 inhibtor. CA-4948 with anti-tumor activity.
  • Description
    Emavusertib is a potent IRAK4/FLT3 inhibtor. CA-4948 with anti-tumor activity.
  • In Vitro
    ——
  • In Vivo
    Animal Model:Mice bearing OCI-LY10 tumorsDosage:25, 50, or 150 mg/kg (once daily), 12.5, 25, or 50 mg/kg (twice daily)Administration:Orally, once daily or twice daily, for 14 consecutive days Result:Induced tumor growth inhibition. Emavusertib administered as a twice-daily divided dose was equivalent to the corresponding once-daily dose with regards to antitumor activity, i.e., 12.5 mg/kg BID versus 25 mg/kg QD.
  • Synonyms
    CA-4948
  • Pathway
    Angiogenesis
  • Target
    FLT
  • Recptor
    FLT3|IRAK4
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    1801344-14-8
  • Formula Weight
    491.5
  • Molecular Formula
    C24H25N7O5
  • Purity
    >98% (HPLC)
  • Solubility
    DMSO:27.78 mg/mL (56.52 mM; Need ultrasonic);H2O:< 0.1 mg/mL (insoluble)
  • SMILES
    CC1=NC=CC(=C1)C2=NC(=CO2)C(=O)NC3=CC4=C(N=C3N5CC[C@H](C5)O)N=C(O4)N6CCOCC6
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Wiese MD, et al. Investigational IRAK-4 inhibitors for the treatment of rheumatoid arthritis. Expert Opin Investig Drugs. 2020 Apr 17:1-8.
molnova catalog
related products
  • AXL-IN-13

    AXL-IN-13 is a potent and orally active AXL inhibitor with an IC50 of 1.6 nM and a Kd of 0.26 nM.

  • FLT3-IN-10

    FLT3-IN-10 (compound 7c) is a potent inhibitor of FMS-like tyrosine kinase 3 (FLT3). FLT3-IN-10 shows the potential for the treatment of FLT3-mutated acute myeloid leukemia (AML).

  • FLT3-IN-2

    FLT3-IN-2 is a FLT3 inhibitor with IC50 of < 1 μM.